Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Short-term Investments · Q2 FY2026 · quarter ended Jun 2026

Short-term investments of $82.3M in Q2 FY2026

Q2 FY2026 short-term investments was $82.3M.

Context

  • Short-term investments amounted to 64.1% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$82.3M-7.9% QoQ
Last fiscal yearDec 2025
$112.08M+189.7% YoY
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+189.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
112.08M USD
Year-over-year change
+189.7%
1-year CAGR
+189.7%

Short-term Investments vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Short-term investments amounts to 64.1% of total assets for ATTO, versus a peer median of 13.2%.
ATTO Competitors
Short-term Investments for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ORKAOruka Therapeutics, Inc.Sep 2026$728.76M USD+182.6%—59.2%
ALMSAlumis Inc. Common StockJun 2026$438.59M USD+31.1%+48.2%78.2%
EVMNEvommune, Inc.Mar 2026$163.15M USD+282.0%—50.6%
ATTOAttovia Therapeutics, Inc.Jun 2026$82.3M USD——64.1%
ACRSAclaris Therapeutics, Inc.Mar 2026$76.76M USD+2.4%-25.7%38.6%
MLTXMoonLake ImmunotherapeuticsMar 2026$59.43M USD-71.5%+22.2%14.8%
ANABAnaptysBio, Inc.Mar 2026$37.99M USD-84.3%-41.7%11.5%
CNTBConnect Biopharma Holdings LimitedDec 2025$6M USD-61.2%-56.6%10.7%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€0 EUR——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 USD——0.0%
ZURAZura Bio LimitedMar 2026$0 USD——0.0%
Peer median (excluding ATTO) —+2.4%-25.7%13.2%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.